A literature review of liver function test elevations in rifampin drug-drug interaction studies.

Clin Transl Sci

Clinical Pharmacology, Global Product Development, Pfizer Inc., San Francisco, California, USA.

Published: July 2022

Although rifampin drug-drug interaction (DDI) studies are routinely conducted, there have been instances of liver function test (LFT) elevations, warranting further evaluation. A literature review was conducted to identify studies in which combination with rifampin resulted in hepatic events and evaluate any similarities. Over 600 abstracts and manuscripts describing rifampin DDI studies were first evaluated, of which 30 clinical studies reported LFT elevations. Out of these, 11 studies included ritonavir in combination with other drug(s) in the rifampin DDI study. The number of subjects that were discontinued from treatment on these studies ranged from 0 to 71 (0-100% of subjects in each study). The number of subjects hospitalized for adverse events in these studies ranged from 0 to 41 (0-83.67% of subjects in each study). LFT elevations in greater than 50% of subjects were noted during the concomitant administration of rifampin with ritonavir-boosted protease inhibitors and with lorlatinib; with labeled contraindication due to observed hepatotoxicity related safety findings only for saquinavir/ritonavir and lorlatinib. In the lorlatinib and ritonavir DDI studies, considerable LFT elevations were observed rapidly, typically within 24-72 h following co-administration. A possible sequence effect has been speculated, where rifampin induction prior to administration of the combination may be associated with increased severity of the LFT elevations. The potential role of rifampin in the metabolic activation of certain drugs into metabolites with hepatic effects needs to be taken into consideration when conducting rifampin DDI studies, particularly those for which the metabolic profiles are not fully elucidated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283752PMC
http://dx.doi.org/10.1111/cts.13281DOI Listing

Publication Analysis

Top Keywords

lft elevations
20
ddi studies
16
rifampin ddi
12
studies
10
rifampin
9
literature review
8
liver function
8
function test
8
rifampin drug-drug
8
drug-drug interaction
8

Similar Publications

Progression of the faecal microbiome in preweaning dairy calves that develop cryptosporidiosis.

Anim Microbiome

January 2025

School of Pharmacy and Life Sciences, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7GJ, UK.

Background: Cryptosporidiosis is a diarrheal disease that commonly affects calves under 6 weeks old. The causative agent, Cryptosporidium parvum, has been associated with the abundance of specific taxa in the faecal microbiome during active infection. However, the long-term impact of these microbiome shifts, and potential effects on calf growth and health have not yet been explored in depth.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic, which began in Wuhan, has notably impacted the respiratory system, but it also affects other organs like the liver, making it one of the deadliest infectious diseases recently.
  • This study compared liver function and inflammation in 200 hospitalized COVID-19 patients to a matched group of healthy controls, revealing that a high number of patients had elevated liver enzymes and inflammatory markers.
  • The findings suggest a significant relationship between COVID-19 and liver health, indicating the need for further research and regular liver function tests for infected patients to guide treatment and monitor their condition.
View Article and Find Full Text PDF

Lyme disease, a tick-borne illness, is caused by the spirochete . Lyme disease commonly presents with the characteristic erythema migrans rash, fever, malaise, headache, and arthralgias. Some patients may have mild liver manifestations, including abnormal liver function tests (LFTs), hyperbilirubinemia, or granulomatous hepatitis.

View Article and Find Full Text PDF

Objective: Liver function test (LFT) abnormalities are higher in patients with severe COVID-19. Most of the studies on this theme were conducted in foreign nations, and the association with LFT abnormalities was not sufficiently addressed in the study areas. Therefore, the current study aimed to investigate the effects of COVID-19 infection on liver function of patients.

View Article and Find Full Text PDF

An account of the current status of point-of-care lateral flow tests for kidney biomarker detection.

Analyst

September 2024

Department of Biosciences and Biomedical Engineering, Indian Institute of Technology, Indore, Khandwa Road, Simrol, Indore - 453552, Madhya Pradesh, India.

Globally, the primary causes of mortality and morbidity related to kidney ailments can be classified as Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD). Biomarker detection can have great potential to improve survival, lower mortality, and reduce the cost of treatment of kidney diseases. Considering the chronic nature of CKD, non-invasive identification and monitoring have proven to be useful.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!